« NY Times Article on Chinese Drywall | Main | Hormone Replacement Therapy (HRT) Class Action Certified in Southern District of California »
October 17, 2012
Stacey Lee on Federal Preemption of Generic-Drug Failure-to-Warn Claims
Professor Stacey Lee (Johns Hopkins, Carey School of Business) has posted to SSRN her article, Pliva v. Mensing: Generic Consumers' Unfortunate Hand, Yale J. Health Pol'y L. & Ethics (forthcoming 2012). Here's the abstract:
The United States Supreme Court held in PLIVA v. Mensing that federal preemption immunizes generic drug manufacturers from liability for state law failure-to-warn claims. As a result, consumers harmed by a mislabeled generic drug will be unable to bring actions against generic manufacturers under state law. The Court confessed that the resulting federal drug-labeling scheme dealt consumers an “unfortunate hand.” By removing generic manufacturers’ duty to improve the adequacy of their products’ warning labels, the Supreme Court calls into question the safety of generic drugs.
BGS
October 17, 2012 in Mass Tort Scholarship, Pharmaceuticals - Misc., Products Liability | Permalink
TrackBack
TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a00d8341bfae553ef017d3cc8a8e2970c
Listed below are links to weblogs that reference Stacey Lee on Federal Preemption of Generic-Drug Failure-to-Warn Claims: